Pharmaceutical care for rare ADR in a patient with ALK-positive non-small cell lung cancer induced by alectinib
- VernacularTitle:1例阿来替尼致ALK阳性NSCLC患者罕见不良反应的药学监护
- Author:
Zhongying DU
1
;
Zhaohong ZHENG
1
;
Liang WEI
2
;
Qiuyu HOU
2
Author Information
1. Dept. of Pharmacy，Qingdao Eighth People’s Hospital，Shandong Qingdao 266100，China
2. Dept. of Cardio-thoracic Surgery，Qingdao Eighth People’s Hospital，Shandong Qingdao 266100，China
- Publication Type:Journal Article
- Keywords:
alectinib;
pleural effusion;
hemolytic anemia;
pharmaceutical care
- From:
China Pharmacy
2024;35(2):247-250
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To provide reference for safe drug use in patients with anaplastic lymphoma kinase （ALK）-positive non-small cell lung cancer （NSCLC）. METHODS Clinical pharmacists participated in the diagnosis and treatment of a patient with ALK-positive NSCLC who developed bilateral pleural effusion and hemolytic anemia after taking alectinib； regarding symptoms such as pleural effusion and hemolytic anemia in the patient， clinical pharmacists investigated the patient’s history of medication and disease， as well as potential drug interaction； to consider the correlation between the patient’s use of alectinib and the duration of pleural effusion and hemolytic anemia， clinical pharmacists suggested that clinical doctors discontinued alectinib and used reduced dose treatment after the pleural effusion improved， but the patient suffered from bilateral pleural effusion and hemolytic anemia again； after evaluating the correlation between alectinib and bilateral pleural effusion and hemolytic anemia using the Naranjo’s assessment scale， clinical pharmacists recommend permanent discontinuation of alectinib and jointly recommend replacement with ensartinib with clinical physicians. RESULTS Physicians adopted the suggestions of clinical pharmacists. The pleural effusion subsequently regressed and hemolytic anemia improved after replacing the drug. The correlation between alectinib and bilateral pleural effusion and hemolytic anemia was confirmed. CONCLUSIONS Clinical pharmacists participate in pharmaceutical monitoring of ALK-positive NSCLC patients， assist clinical doctors in developing personalized medication recommendations， and ensure the safety of patient medication.
